https://orcid.org/0000-0003-2895-9283
References
- Remon J, Pignataro D, Novello S, et al. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer. Cancer Treat Rev. 2021 Apr;95:102178.
- Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019 Aug 27;322(8):764–774.
- Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4;371(23):2167–2177. doi: 10.1056/NEJMoa1408440
- Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963–1971. doi: 10.1056/NEJMoa1406766
- Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017 Oct 25;17(11):637–658.
- Liu X, Zhang L, Wan H, et al. Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations. Bioorg Med Chem Lett. 2022 Jun 15;66:128730.
- Shi Y, Chen J, Zhang H, et al. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC Med. 2023 Feb 24;21(1):72. doi: 10.1186/s12916-023-02738-5
- Park BK, Boobis A, Clarke S, et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov. 2011 Apr;10(4):292–306.
- Penner N, Xu L, Prakash C. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol. 2012 Mar 19;25(3):513–31.
- Yan G, Yang D, Yu Y, et al. Pharmacokinetics of gene recombined angiogenesis inhibitor Kringle 5 in vivo using (131)I specific markers and SPECT/CT. J Pharm Anal. 2016 Oct;6(5):313–317.
- Roffey SJ, Obach RS, Gedge JI, et al. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007;39(1):17–43. doi: 10.1080/03602530600952172
- Liu X, Feng D, Zheng M, et al. Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins. Drug Metab Pharmacokinet. 2020 Oct;35(5):456–465.
- Shi Y, Fang J, Hao X, et al. Safety and activity of WX-0593 (iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022 Jan 28;7(1):25. doi: 10.1038/s41392-021-00841-8
- Penner N, Klunk LJ, Prakash C. Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos. 2009 May;30(4):185–203. doi: 10.1002/bdd.661
- Lu J, Pan Q, Zhou J, et al. Pharmacokinetics, distribution, and excretion of sodium oligomannate, a recently approved anti-Alzheimer’s disease drug in China. J Pharm Anal. 2022 Feb;12(1):145–155.
- Hop CE, Wang Z, Chen Q, et al. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci. 1998 Jul;87(7):901–903.
- Bian Y, Zhang H, Ma S, et al. Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects. Br J Clin Pharmacol. 2021 Jan;87(1):93–105.
- Bian Y, Meng J, Ma S, et al. Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers. Br J Clin Pharmacol. 2022 Jul;88(7):3307–3320.
- 21 CFR 361.1 [Internet]. 2023. https://www.fda.gov/drugs/science-and-research-drugs/radioactive-drug-research-committee-rdrc-program
- Weaver RJ, Blomme EA, Chadwick AE, et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov. 2020 Feb;19(2):131–148.
- Aldini G, Altomare A, Baron G, et al. N-acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018 Jul;52(7):751–762.